GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

Philipp Sievers; Damian Stichel; Martin Sill; Daniel Schrimpf; Dominik Sturm; Florian Selt; Jonas Ecker; Daniel Kazdal; Evelina Miele; Mariëtte E.G. Kranendonk; Bastiaan B.J. Tops; Patricia Kohlhof-Meinecke; Rudi Beschorner; Christof M. Kramm; Martin Hasselblatt; Guido Reifenberger; David Capper; Pieter Wesseling; Albrecht Stenzinger; Till Milde; Andrey Korshunov; Olaf Witt; Stefan M. Pfister; Wolfgang Wick; Andreas von Deimling; David T.W. Jones; Felix Sahm

doi:10.1007/s00401-021-02369-1

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

Philipp Sievers
, Damian Stichel
, Martin Sill
, Daniel Schrimpf
, Dominik Sturm
, Florian Selt
, Jonas Ecker
, Daniel Kazdal
, Evelina Miele
, Mariëtte E.G. Kranendonk
, Bastiaan B.J. Tops
, Patricia Kohlhof-Meinecke
, Rudi Beschorner
, Christof M. Kramm
, Martin Hasselblatt
, Guido Reifenberger
, David Capper
, Pieter Wesseling
, Albrecht Stenzinger
, Till Milde

Andrey Korshunov, Olaf Witt, Stefan M. Pfister, Wolfgang Wick, Andreas von Deimling, David T.W. Jones, Felix Sahm

Research related

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

19 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	1065-1069
Aantal pagina's	5
Tijdschrift	Acta Neuropathologica
Volume	142
Nummer van het tijdschrift	6
DOI's	https://doi.org/10.1007/s00401-021-02369-1
Status	Gepubliceerd - dec. 2021

Toegang tot document

10.1007/s00401-021-02369-1

Citeer dit

Sievers, P., Stichel, D., Sill, M., Schrimpf, D., Sturm, D., Selt, F., Ecker, J., Kazdal, D., Miele, E., Kranendonk, M. E. G., Tops, B. B. J., Kohlhof-Meinecke, P., Beschorner, R., Kramm, C. M., Hasselblatt, M., Reifenberger, G., Capper, D., Wesseling, P., Stenzinger, A., ... Sahm, F. (2021). GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 142(6), 1065-1069. https://doi.org/10.1007/s00401-021-02369-1

@article{cfa1fbfbe23a410dbc4d565bcc5ad88c,

title = "GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types",

author = "Philipp Sievers and Damian Stichel and Martin Sill and Daniel Schrimpf and Dominik Sturm and Florian Selt and Jonas Ecker and Daniel Kazdal and Evelina Miele and Kranendonk, \{Mari{\"e}tte E.G.\} and Tops, \{Bastiaan B.J.\} and Patricia Kohlhof-Meinecke and Rudi Beschorner and Kramm, \{Christof M.\} and Martin Hasselblatt and Guido Reifenberger and David Capper and Pieter Wesseling and Albrecht Stenzinger and Till Milde and Andrey Korshunov and Olaf Witt and Pfister, \{Stefan M.\} and Wolfgang Wick and \{von Deimling\}, Andreas and Jones, \{David T.W.\} and Felix Sahm",

note = "Funding Information: We thank J. Meyer, L. Hofmann and A. Habel for skillful technical assistance and the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing Illumina DNA methylation array-related services. This study was supported by the Hertie Network of Excellence in Clinical Neuroscience. P.S. is a fellow of the Hertie Academy of Excellence in Clinical Neuroscience. D.T.W.J. is supported by the Everest Centre for Low-Grade Paediatric Brain Tumours (the Brain Tumour Charity, UK; GN-000382). Funding Information: We thank J. Meyer, L. Hofmann and A. Habel for skillful technical assistance and the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing Illumina DNA methylation array-related services. This study was supported by the Hertie Network of Excellence in Clinical Neuroscience. P.S. is a fellow of the Hertie Academy of Excellence in Clinical Neuroscience. D.T.W.J. is supported by the Everest Centre for Low-Grade Paediatric Brain Tumours (the Brain Tumour Charity, UK; GN-000382).",

year = "2021",

month = dec,

doi = "10.1007/s00401-021-02369-1",

language = "English",

volume = "142",

pages = "1065--1069",

journal = "Acta Neuropathologica",

issn = "0001-6322",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

Sievers, P, Stichel, D, Sill, M, Schrimpf, D, Sturm, D, Selt, F, Ecker, J, Kazdal, D, Miele, E, Kranendonk, MEG, Tops, BBJ, Kohlhof-Meinecke, P, Beschorner, R, Kramm, CM, Hasselblatt, M, Reifenberger, G, Capper, D, Wesseling, P, Stenzinger, A, Milde, T, Korshunov, A, Witt, O, Pfister, SM, Wick, W, von Deimling, A, Jones, DTW & Sahm, F 2021, 'GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types', Acta Neuropathologica, vol. 142, nr. 6, blz. 1065-1069. https://doi.org/10.1007/s00401-021-02369-1

TY - JOUR

T1 - GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

AU - Sievers, Philipp

AU - Stichel, Damian

AU - Sill, Martin

AU - Schrimpf, Daniel

AU - Sturm, Dominik

AU - Selt, Florian

AU - Ecker, Jonas

AU - Kazdal, Daniel

AU - Miele, Evelina

AU - Kranendonk, Mariëtte E.G.

AU - Tops, Bastiaan B.J.

AU - Kohlhof-Meinecke, Patricia

AU - Beschorner, Rudi

AU - Kramm, Christof M.

AU - Hasselblatt, Martin

AU - Reifenberger, Guido

AU - Capper, David

AU - Wesseling, Pieter

AU - Stenzinger, Albrecht

AU - Milde, Till

AU - Korshunov, Andrey

AU - Witt, Olaf

AU - Pfister, Stefan M.

AU - Wick, Wolfgang

AU - von Deimling, Andreas

AU - Jones, David T.W.

AU - Sahm, Felix

N1 - Funding Information: We thank J. Meyer, L. Hofmann and A. Habel for skillful technical assistance and the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing Illumina DNA methylation array-related services. This study was supported by the Hertie Network of Excellence in Clinical Neuroscience. P.S. is a fellow of the Hertie Academy of Excellence in Clinical Neuroscience. D.T.W.J. is supported by the Everest Centre for Low-Grade Paediatric Brain Tumours (the Brain Tumour Charity, UK; GN-000382). Funding Information: We thank J. Meyer, L. Hofmann and A. Habel for skillful technical assistance and the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing Illumina DNA methylation array-related services. This study was supported by the Hertie Network of Excellence in Clinical Neuroscience. P.S. is a fellow of the Hertie Academy of Excellence in Clinical Neuroscience. D.T.W.J. is supported by the Everest Centre for Low-Grade Paediatric Brain Tumours (the Brain Tumour Charity, UK; GN-000382).

PY - 2021/12

Y1 - 2021/12

UR - https://www.scopus.com/pages/publications/85115177261

U2 - 10.1007/s00401-021-02369-1

DO - 10.1007/s00401-021-02369-1

M3 - Letter

C2 - 34536122

AN - SCOPUS:85115177261

SN - 0001-6322

VL - 142

SP - 1065

EP - 1069

JO - Acta Neuropathologica

JF - Acta Neuropathologica

IS - 6

ER -